Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data

Affiliations

• ¹ Division of Infectious Diseases, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
• ² Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA.
• ³ University of Maryland Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
• ⁴ National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
• ⁵ Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
• ⁶ Department of Medicine, Division of Infectious Diseases, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, USA.
• ⁷ Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA.
• ⁸ Division of Infectious Diseases, University of Texas Health San Antonio and University Health, San Antonio, Texas, USA.
• ⁹ Department of Medicine, Division of Infectious Diseases, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
• ¹⁰ Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
• ¹¹ Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA.
• ¹² Department of Medicine, Infectious Disease, Duke University Medical Center, Durham, North Carolina, USA.
• ¹³ National Centre for Infectious Diseases; Tan Tock Seng Hospital; Yong Loo Lin School of Medicine; Lee Kong Chian School of Medicine; Singapore.
• ¹⁴ Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, California, USA.